glp 1 afib New research presented at #HRS2026 finds #GLP1 medications may reduce the risk of #AFib — independent of weight loss. The findings suggest these therapies may influence heart rhythm through mechanisms beyond weight GLP-1 receptor agonists confer better

GLP-1RAs can cross the bloodbrain barrier and activate brain GLP-1 receptors, leading to neuroprotection by improving insulin signaling, reducing tau hyperphosphorylation, and enhancing cognitive function in diabetic and aging models

L- ,

Saka R, Jain H, Kommineni N, Chella N, Khan W

As with all chronic diseases, it would be much more profitable to prevent obesity than to cure it by attacking the causes of this overweight as a priority, rather than devoting all our efforts and financial means to their treatment

In another trial, higher levels of PYY 3-36 were also observed relative to baseline after 16 weeks of treatment with liraglutide 3.0 mg [34]